Drug Patent Watch
MARCH 22, 2022
FEATURED ARTICLE Branded Generics Promise Profits for Drugmakers, Peace of Mind for Patients Developing nations offer welcoming and growing markets as Abbott focuses exclusively on reformulating and marketing off-patent medications…. The post DrugPatentWatch Week in Review appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Today
MARCH 30, 2022
The topic of this month’s newsletter from Drug Discovery Today is “Epigenetics”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
MARCH 18, 2022
Today’s guest post comes from Ashwin Mundra, Chief Revenue Officer at Kalderos. As Ashwin explains, manufacturers face a gap between visible, non-compliant drug discounts and the actual level of non-compliant discounts. He describe Kalderos’ technology-enabled, machine learning-based methods for identifying drug discount non-compliance. To learn more, register to receive a copy of Kalderos’ annual report, available April 13, 2022: Conquering the “Great Unknown”: Connecting the data gaps that kee
Eye on FDA
MARCH 30, 2022
Tectonic pandemic plates are shifting respecting the COVID-19 pandemic. For weeks now we have been watching caseloads in the United States broadly fall. It feels as if we are indeed shifting gears. There are other moving parts that are in motion as well. It is a fundamental re-shifting of the landscape. And there are consequences. First, government funding supporting access to vaccination and treatment for COVID has run out and so far, is not replenished.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Crown Bioscience
MARCH 31, 2022
This post explores the benefits of combining high-content imaging (HCI) and high-content analysis (HCA) with 3D in vitro tumor organoids for drug discovery and validation studies. An increasing number of large in vitro screening studies are showing that novel clinically relevant biomarkers of drug response and important drug effects can be discovered by probing a wider array of cellular parameters combined with dose–response assessments.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Patent Watch
MARCH 22, 2022
Drugs contain ingredients with therapeutic activity, so-called “active ingredients” as well as inactive ingredients. These inactive ingredients, called excipients, are included in oral products for various reasons, such as to…. The post 2 Strategies to Grow Your Excipient Business by Tracking Drug Patents appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Today
MARCH 28, 2022
Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders
Drug Channels
MARCH 15, 2022
I am pleased to announce our new 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Examines Consolidation and Vertical Integration of U.S.
The Pharma Data
MARCH 31, 2022
Planned investments of around €2bn over next three years / Shift of resources into strategic pharmaceutical areas by investing in key production sites, manufacturing technologies and supply chain network / Bayer is transforming its pharmaceutical division through enhanced focus on breakthrough innovation as well as through consolidation and modernization of its business operations.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Olympian Clinical Research
MARCH 31, 2022
Anxiety is the most common mental illness in the United States, affecting over 40 million adults every year. With anxiety at an all-time high as we live through a pandemic and an increasingly globalized and technologically advanced world, it can be challenging to understand what type of anxiety you may be experiencing. The most common types of anxiety are social and general anxiety, but how can you tell the difference?
Practical Cheminformatics
MARCH 28, 2022
Clustering Fragment Screening Hits With a Self-Organizing Map (SOM) In a paper, " Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking ", published last year by scientists from UCSF and the Diamond Light Source, the authors reported more than 200 structures of fragments bound to the Nsp3 macrodomain of SARS-CoV-2.
Drug Patent Watch
MARCH 16, 2022
Annual Drug Patent Expirations for XYREM Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for Jazz Pharms drug XYREM appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Today
MARCH 28, 2022
Science Minister George Freeman says life sciences have an essential part to play in creating the economy and ecosystem of tomorrow.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Channels
MARCH 1, 2022
The Centers for Medicare & Medicaid Services (CMS) has recently released its 2022 data on enrollment in Medicare Part D prescription drug plans (PDPs). Our exclusive analysis of these numbers finds that for 2022, an astounding 99% of seniors are enrolled in the wonderland of PDPs with preferred pharmacy networks. Below, we use the new enrollment data to examine the major pharmacy chains’ position within the 27 major Part D plans that have preferred networks.
The Pharma Data
MARCH 31, 2022
French AMF approved EUROAPI’s listing prospectus EUROAPI first day of trading expected to occur on May 6, 2022 subject to the approval of the Distribution by the Ordinary and Extraordinary Shareholders’ Meeting to be held on May 3, 2022 Sanofi will host today a dedicated Capital Markets Day at 1:30 pm CET to present EUROAPI’s business in greater detail The Distribution ratio will be one (1) EUROAPI share per twenty three (23) Sanofi shares After the Distribution, Sanofi has confirmed its intenti
Sygnature Discovery
MARCH 24, 2022
When DMPK scientist Lynette Ongeri joined Sygnature this month, she unknowingly helped us reach a landmark we couldn’t be prouder of… Sygnature Discovery – or Sygnature Chemical Services Ltd, as it was known then – opened its doors in 2004 with five colleagues. Sygnature’s first logo Led by founder Simon Hirst, this ambitious small Chemistry group hit the ground running, quickly developing strong relationships with customers and expanding into other scientific specialities like Computation
EG Life Sciences
MARCH 21, 2022
Throughout the Biopharma industry, organizations are applying Agile principles and practices to get drugs to market faster and keep up with demands following the pandemic. Eliassen Group and EG Life Sciences have been working hand in hand with experts in many different fields – not just IT – to ensure that these organizations successfully achieve the benefits of enterprise agility.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
MARCH 6, 2022
This chart shows the pharmaceutical companies with the most cream dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most cream dosed drugs…. The post Which pharmaceutical companies have the most cream dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Today
MARCH 24, 2022
The ranking was calculated on cost and time efficiencies and United States was shown to be the most efficient jurisdiction on speed of business whereas Brazil, South Korea and China scored less favorably
Drug Channels
MARCH 8, 2022
Next week, Drug Channels Institute will release our 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. It’s the 13th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system. The exhibit below—one of 216 in our new report—provides a first look at the 15 largest organizations, ranked by total U.S. prescription dispensing revenues for calendar year 2021.
The Pharma Data
MARCH 31, 2022
Through Save Legs. Change Lives. ™, Janssen seeks to elevate PAD research, collaboration, education and screening for communities placed at increased risk of cardiovascular disease. The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the launch of Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now, a multi-year initiative aimed at creating urgency and action to address the hidden threat of peripheral artery disease (PAD)-related amputation, with an initial fo
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
The Strateos Blog: Drug Discovery
MARCH 18, 2022
Strateos had the pleasure of participating at the PharmaIQ Live: Smartlab Digital 2022 conference held between March 8-9th, which focused on the potential of Lab 4.0 strategies to increase the speed, efficiency and reduce the cost of the drug discovery process. John Harman, Sr. Director of Product Management at Strateos, with over 30 years of small molecule drug discovery experience, gave a talk where he outlined key industry pain points and how cloud labs can provide solutions by increasing con
Tecan
MARCH 17, 2022
By Dajana Domik Neopterin is a broad range inflammation marker which can be measured in the blood of patients and indicates a multitude of diseases from acute viral infections to autoimmune conditions. 1 This marker can serve as an essential “catch all” as neopterin levels are elevated due to any viral or bacterial invasion, which indicates an infection within the body without the need of several specific tests to confirm.
Drug Patent Watch
MARCH 2, 2022
Annual Drug Patent Expirations for TEKTURNA+HCT Tekturna Hct is a drug marketed by Noden Pharma and is included in one NDA. It is available from one supplier. There are two…. The post New patent expiration for Noden Pharma drug TEKTURNA HCT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Today
MARCH 10, 2022
Heidelberg, 10 March 2022 Molecular Health and collaborators at the University of Florida College of Pharmacy, Takeda Oncology, and thinkQ² published a triad of articles that describe and prove the concept of a novel systems approach to elucidate molecular mechanisms of drug toxicities using real-world data (RWD).
Drug Channels
MARCH 4, 2022
Today’s guest post comes from Miranda Gill, Vice President of Network at CoverMyMeds. Miranda discusses how integrated technology solutions can be used at critical moments in the patient’s journey to increase access, affordability, and adherence to therapies. To learn more about CoverMyMeds’ prescription decision support tools for the entire care team, visit CoverMyMeds at HIMSS22.
Expert insights. Personalized for you.
120 
Let's personalize your content